GV (Google Ventures)

Activity from announced rounds

Activity in this selectionSeries C+

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
14
Confirmed lead rounds
1
9 roles undisclosed
New companies
12
First participation on record · 2 follow-on
Funding in participating rounds
$3.1B
14 disclosed · full round size, not this investor’s share

By stage

Series C+14

By primary sector

AI4
Biotech3
Healthtech3
Cybersecurity2
Developer tools1
1 more
Foodtech1

By country

United States11
United Kingdom3

Rounds

14 in this selection
Blacksmith

Cloud infrastructure for building and testing software through continuous integration workflows.

$66MSeries C
Participant
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
Metaview

Metaview provides AI agents and software for recruiters and hiring teams, from candidate sourcing and screening to interview notes and reporting.

$60MSeries C
Participant
Snorkel AI

Snorkel AI helps enterprises build expert-curated training data and benchmarks for advanced AI models and agents.

$350MSeries E
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Lead
Obsidian Security

Secures non-human identities and AI agents operating in third-party applications

$85MSeries D
Role not disclosed
Wonder

A leading food technology platform built to make great food more accessible

$650MSeries D
Role not disclosed
Iterative Health

Develops technology and services for clinical research.

$77MSeries C
Role not disclosed
Censys

Provides Internet intelligence and insights for security operations and exposure management

$70MSeries D
Role not disclosed
SambaNova

Provides next-generation AI infrastructure for enterprises, neo-clouds, and sovereign AI initiatives

$350MSeries E
Role not disclosed
Midi Health

Provides accessible, insurance-covered services in all 50 states for women's healthcare

$100MSeries D
Role not disclosed
Synthesia

Develops AI-powered digital avatars for corporate clients

$200MSeries E
Role not disclosed
OpenEvidence

Provides AI-powered medical search engine for clinicians

$250MSeries D
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed